Arthritis Res Ther Volume 6 Issue 4 |
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
CommentaryPerspectives and limitations of gene expression profiling in rheumatology: new molecular strategiesThomas Häupl1 , Veit Krenn2, Bruno Stuhlmüller1, Andreas Radbruch3 and Gerd R Burmester1 1Department of Rheumatology, Charité, Berlin, Germany 2Institute for Pathology, Charité, Berlin, Germany 3German Arthritis Research Centre (DRFZ), Berlin, Germany author email corresponding author email
Arthritis Res Ther 2004,
6:140-146doi:10.1186/ar1194 Abstract
The deciphering of the sequence of the human genome has raised the expectation of unravelling the specific role of each gene in physiology and pathology. High-throughput technologies for gene expression profiling provide the first practical basis for applying this information. In rheumatology, with its many diseases of unknown pathogenesis and puzzling inflammatory aspects, these advances appear to promise a significant advance towards the identification of leading mechanisms of pathology. Expression patterns reflect the complexity of the molecular processes and are expected to provide the molecular basis for specific diagnosis, therapeutic stratification, long-term monitoring and prognostic evaluation. Identification of the molecular networks will help in the discovery of appropriate drug targets, and permit focusing on the most effective and least toxic compounds. Current limitations in screening technologies, experimental strategies and bioinformatic interpretation will shortly be overcome by the rapid development in this field. However, gene expression profiling, by its nature, will not provide biochemical information on functional activities of proteins and might only in part reflect underlying genetic dysfunction. Genomic and proteomic technologies will therefore be complementary in their scientific and clinical application. |